Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immuron Limited IMRN
$2.27
-$0.21 (-9.05%)
На 18:01, 12 мая 2023
Ключевые показатели
-
Marketcap
14123501.00000000
-
week52high
3.21
-
week52low
1.39
-
Revenue
765193
-
P/E TTM
-6
-
Beta
1.32786200
-
EPS
-0.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 авг 2022 г. в 04:00
Описание компании
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| H.C. Wainwright | Buy | 18 окт 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment
Market Watch
08 мая 2023 г. в 06:35
The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmaceutical company said the U.S. Food and Administration has removed a clinical hold on the Investigational New Drug (IND) application for its diarrhea treatment.
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
GlobeNewsWire
02 мая 2023 г. в 06:00
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore.
Immuron CEO highlights strong sales growth in business update presentation
Proactive Investors
06 мар 2023 г. в 22:56
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore highlighted the strong growth in sales of oral immunotherapeutic products in the company's February 2023 business update presentation for investors. Lydeamore noted that the company posted revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.
The Top Indicators That Penny Stocks Traders Use
PennyStocks
25 дек 2022 г. в 11:30
Use these indicators for buying penny stocks in 2022 The post The Top Indicators That Penny Stocks Traders Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Immuron CEO, Steven Lydeamore to present at AusBioInvest
GlobeNewsWire
26 окт 2022 г. в 06:00
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore.